[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100350360":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":21,"responsibleParty":60,"collaborators":7,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":7,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":7,"enrollmentInfo":71,"targetDuration":7,"studyType":74,"phases":7,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Centre Leon Berard","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Matthieu SARABI, Dr","PRINCIPAL_INVESTIGATOR",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Gwenaelle GARIN","CONTACT","04 26 55 68 24","gwenaelle.garin@lyon.unicancer.fr",{"name":10,"role":15,"phone":19,"phoneExt":7,"email":20},"04 69 85 75 82","matthieu.sarabi@lyon.unicancer.fr",[22,39,50],{"facility":23,"status":24,"city":25,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Hopital Saint Joseph Saint Luc","RECRUITING","Lyon","69007","France","FR",{"type":30,"coordinates":31},"Point",[32,33],4.84789,45.74906,{"lat":33,"lon":32},[36],{"name":37,"role":15,"phone":7,"phoneExt":7,"email":38},"MILOU Fabrice, Dr","fmilou@saintjosephsaintluc.fr",{"facility":40,"status":24,"city":25,"state":7,"zip":41,"country":27,"countryCode":28,"cosmosGeoPoint":42,"geoPoint":44,"contacts":45},"Clinique de L'Infirmerie Protestante","69004",{"type":30,"coordinates":43},[32,33],{"lat":33,"lon":32},[46],{"name":47,"role":15,"phone":48,"phoneExt":7,"email":49},"GARBIT Vincent, Dr","04 72 00 71 65","vincent.garbit@infirmerie-protestante.com",{"facility":5,"status":24,"city":25,"state":7,"zip":51,"country":27,"countryCode":28,"cosmosGeoPoint":52,"geoPoint":54,"contacts":55},"69008",{"type":30,"coordinates":53},[32,33],{"lat":33,"lon":32},[56],{"name":57,"role":15,"phone":58,"phoneExt":7,"email":59},"Lucas DE CRIGNIS, Dr","04 78 78 28 28","Lucas.decrignis@lyon.unicancer.fr@lyon.unicancer.fr",{"type":61,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100350360","colon-im--microbiota-and-immune-infiltrate-in-normal-dysplastic-and-neoplastic-colorectal-tissue-100350360",false,"NCT03841799","COLON-IM : Microbiota and Immune Infiltrate in Normal, Dysplastic and Neoplastic Colorectal Tissue","COLON-IM : Prospective Cohort Study About Colorectal Environment : Microbiota and Immune Infiltrate in Normal, Dysplastic and Neoplastic Colorectal Tissue","Inclusion Criteria:\n\n* I1. Male or female patient 18 age or older at time of inform consent signature.\n* I2. Patient Cohort A : with benign or malignant colorectal lesion (from stage I to III according to TNM\u002FUICC classification) eligible to surgery, not previously be treated with an anticancer systemic agent (any type) and not be previously exposed to radiotherapy.\n\nCohort B : with localised colon\u002Frectume adenocarcinoma, eligible to surgery, and treated by radiotherapy and\u002For pre-operative chemotherapy\n\n* I3. Patient should be able and willing to comply with procedures as per protocol.\n* I4. Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed.\n* I5. Patient must be covered by a medical insurance.\n\nExclusion Criteria:\n\n* E1. Pregnant or breast-feeding female patient.\n* E2. Prior treatment with : Any immunomodulatory treatment (streroids, immunosuppressive therapies) within 4 weeks prior inclusion, Any antibiotics within 8 weeks prior inclusion.\n* E3. Patients with secondary malignancy unless this malignancy is not expected to interfere with the evaluation of study endpoints and is approved by the sponsor. Examples of the latter include: in-situ carcinoma of the cervix treated adequately, basal or squamous cell carcinoma of the skin. Patients previously treated for another cancer type and without evidence of relapse for at least 1 year are eligible.\n* E4. Patient with inflammatory disease or autoimmune disease.\n* E5. Patient under curatorship, guardianship or judicial protection.","ALL","18 Years",{"count":72,"type":73},400,"ESTIMATED","OBSERVATIONAL","The primary objective of COLON-IM is to describe colorectal tissue microenvironment (neutrophils infiltrate) of patients with benign or malignant colorectal lesion (from stage I to III according to Tumor Node Metastasis (TNM)\u002F Union for International Cancer Control (UICC) classification).",[77],"Colorectal Cancer",[79,80,81],"Microbiota","Microenvironment colorectal tissue","Immune infiltrate","2026-04-21",{"date":84,"type":85},"2026-04-24","ACTUAL",{"date":87,"type":85},"2019-05-02",{"date":89,"type":73},"2029-12",{"name":5,"class":6},3]